ArticleJournal of molecular modeling2025
Computable properties of selected monomeric acylphloroglucinols with anticancer and/or antimalarial activities and first-approximation docking study.
Article in Journal of molecular modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gmelinol ameliorates type 2 diabetes and multi-organ complications in streptozotocin-nicotinamide-induced diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextMalaria and cancer tend to become drug-resistant a few years after a drug is introduced into clinical use. This prompts the search for new molecular structures that are sufficiently different from the drugs for which resistance has developed. The present work considers eight selected acylphloroglucinols (ACPLs) with proven antimalarial and/or anticancer activities. ACPLs are compounds of natural origin structurally derivative from 1,3,5-trihydroxybenzene and characterized by the presence of an acyl group R-C = O. The selected ACPLs contain only one acylphloroglucinol moiety and are, therefore, monomeric ACPLs (also occasionally called "simple" ACPLs). They were studied computationally in vacuo and in-three-solvents with different polarities, using different levels of theory. The findings on molecular properties relevant to the understanding of biological activities align with previous studies, enhancing the reliability of predictions for molecules of the same class and providing insights into their behaviour in different environments. Structure-based virtual screening was used to study the interactions between these molecules and selected proteins known as relevant drug targets for antimalarial and anticancer activities; the screening showed that most of these ACPLs bind well with the selected proteins, thus being interesting for further studies. The results also suggest that most of these ACPLs have the potential for dual therapeutic applications (antimalarial and anticancer), offering a cost-effective drug development option. Furthermore, the ADME-T predictions indicated favourable pharmacokinetic properties for these ACPLs.
methodsComputational studies of the selected ACPLs were performed using Gaussian-09, in vacuo and in-three-solvents with different polarities. Three different levels of theory were used - Hartree Fock (HF), Density Functional Theory (DFT) with the B3LYP functional, and second order Møller-Plesset Perturbation Theory (MP2). HF and MP2 used a 6-31G(d,p) basis set, while DFT used a 6-31G + (d,p), for consistency with previous studies on ACPLs. The investigated molecular properties include conformational preferences, intramolecular hydrogen bonding patterns, HOMO-LUMO energy gap, dipole moments, as well as the solvent effect for the three considered solvents. Virtual screening was conducted using the Schrödinger suite, including Maestro 9.3 with GLIDE for docking and GlideScore for evaluating binding affinities. In addition, the QikProp tool provided ADME-T predictions for pharmacokinetic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.